Importance of adding ADT to brachy boost therapy for men with unfavorable-risk prostate cancer

Last month, we looked at Level 1 evidence (highest level, superseding all previous studies) that for unfavorable-risk patients, brachy boost therapy (BBT) — i.e., external beam therapy (EBRT) with a brachytherapy boost to the prostate — has better results when accompanied by 18 months of androgen deprivation therapy (ADT) (see this link). … READ MORE …

Are you willing to talk about your late-stage mCRPC journey?

A company that is developing new forms of targeted treatment for late-stage prostate cancer is seeking some help from one or two members of the prostate cancer patient community. … READ MORE …

Data from HERO trial reported — at virtual ASCO and in NEJM

The results of the Phase III HERO trial of relugolix — the first oral LHRH antagonist for treatment of advanced prostate cancer — have now been reported in the New England Journal of Medicine (NEJM) and at the “virtual” annual meeting of the American Society for Clinical Oncology (ASCO). … REAR MORE …

And now … FDA approves second PARP inhibitor for selected men with mCRPC

Following last week’s approval of rucaparib (Rubraca), the US Food and Drug Administration (FDA) has now, also, approved the PARP inhibitor olaparib (Lynparza) for the treatment of men with with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. … READ MORE …

FDA approves first PARP inhibitor for selected men with mCRPC

Yesterday evening the US Food and Drug Administration (FDA) approved rucaparib (Rubraca) for the treatment of men with BRCA1/2-mutant, metastatic, castration-resistant prostate cancer (mCRPC) who have also already been treated with androgen receptor-directed therapy and taxane-based chemotherapy. … READ MORE …

Prostate cancer and coronavirus (COVID-19)

So — rather obviously — the web has been swamped with information about COVID-19 over the past 2 months or more. That information runs the gamut from very accurate, well-constructed guidance to utter garbage, and it would have been impossible for us to sort it all out for you. So we haven’t tried. … READ MORE …

Sipuleucel-T in management of favorable-risk prostate cancer: the ProVent trial

At the end of last year, Dendreon announced that the Phase III ProVent trial of sipuelucel-T (Provenge) in the treatment of men with relatively lower-risk forms of prostate cancer (as compared to active surveillance) had been fully enrolled ahead of schedule. … READ MORE …

Axumin-based PET/CT scans and detection of recurrent prostate cancer

A new report from a relatively small, single-institution study has provided additional information about the utility of [18F]fluciclovine (Axumin) PET/CT scans in the detection of recurrent prostate cancer after definitive first-line treatment. … READ MORE …

More negative data for checkpoint inhibition in treatment of mCRPC

Alas … once again we hear that the combination of  androgen receptor blockade (with enzalutamide/Xtandi) + a checkpoint inhibitor (the PD-L1 inhibitor atezolizumab/Tecentriq) has had no clinically meaningful impact on the overall survival (OS) of men with metastatic, castration-resistant prostate cancer (mCRPC) compared to enzalutamide alone. … READ MORE …

Olaparib in treatment of men with mCRPC and selected HRR gene mutations

According to a media release issued by AstraZeneca and Merck on Friday evening, olaparib (Lynparza) has shown “a statistically significant and clinically meaningful improvement in … overall survival (OS)” in men with metastatic, castration-resistant prostate cancer (mCRPC) and BRCA1/2 or ATM gene mutations (homologous repair gene mutations or HRRm). … READ MORE …

Alas … PPV not good for PI-RADS at all

For the past few years, some of us have been quietly concerned about the true value of MRI scans and the accuracy of PI-RADS scores in evaluation of a patient’s risk for the presence of clinically significant prostate cancer. This is a complex issue … but data from a large, recently completed study has now validated these concerns. … READ MORE …

Will the FDA approve an oral LHRH antagonist for treatment of prostate cancer?

According to a media release issued yesterday, Myovant Sciences (based in Basel, Switzerland) has submitted a New Drug Application (NDA) for approval of its oral LHRH antagonist, relugolix, in the treatment of men with advanced prostate cancer. … READ MORE …

Focal therapy for localized prostate cancer: the “state of the art”

In a report on the UroToday web site, John Fortin, a prostate cancer patient who chose to have focal therapy himself a while ago, has reported on information presented at the 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, which was held in Washington, DC, in February this year. … READ MORE …

Long-term adjuvant ADT improves results of brachy-boost therapy in unfavorable-risk prostate cancer patients

TROG 01.03 RADAR, begun in 2003, was a (partly) randomized clinical trial to help optimize therapy of unfavorable-risk patients. … READ MORE …

Is Howard done with biopsies “forever”?

One of the questions that has been nagging at Howard Wolinsky for a while now is whether he really needs to have another biopsy … ever! … READ MORE …